documents

/Tag:documents
­

Bionaturis Group FY-2017 audited results

Highlights

Reports net sales of €2.39 million, +82% YoY
Reports EBITDA of €1.07 million, + €1.50 million YoY
Reports 82% of gross margin over net sales versus 71% in FY-2016
Reports the binding integration agreement with ADL Biopharma to create an European benchmark in the development and manufacturing of biological products
Reports a commercial and supply license agreement of non-prescription products for livestock with minimum annual orders worth of € 4.77 million
Reports the executions of an exclusive license agreement for the development, registration, manufacturing, and commercialization of BNT005 in Argentina and Paraguay.
Reports the signing of an Evaluation and Licensing agreement with exclusive worldwide license rights (except in Argentina and Paraguay) for the development, registration and commercialization of BNT005 with a top leading company in the sector
Reports ZIP patents granted in USA, EUROPE and JAPAN
Reports reaching an E&O agreement with a global leader for the exclusive development, registration and marketing of a probiotic for oral application, indicated to improve oral health in companion animals
Reports the signing by Biobide of new relevant contracts with three leading companies in the agrochemical and biomedicine sectors, for a cumulative amount worth of USD 1.39 million
Reports BNT005 patent granted in CHINA

 Click here to see the official document.

April 27th, 2018|Blog english|Comments Off on Bionaturis Group FY-2017 audited results

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR